Immunosuppressive treatment of early-stage interstitial lung disease (ILD) in people with systemic sclerosis may be a potential therapeutic option to prevent ILD progression, a study suggests. The study, “Association between immunosuppressive therapy and course of mild interstitial lung disease…
Some people with systemic sclerosis (SSc) are protected from cancer development by the presence of anti-RNA polymerase I autoantibodies, a study suggests. The study, “Scleroderma patients with antibodies against the large subunits of both…
Abatacept, a potential treatment for people with early-stage diffuse cutaneous systemic sclerosis (dcSSc), showed clinically significant improvements in patients’ functional ability and overall health, despite failing to significantly reduce skin thickening, a Phase 2 study concluded. The study, “Abatacept…
Get regular updates to your inbox.